Experimental study of systemic hemostatic effects of fibrin monomer in inhibition of platelet aggregation function

Aim. The study objective was to examine fibrin monomer hemostatic effects in post-traumatic parenchymal hemorrhage in the setting of pharmacologically associated platelet aggregation inhibition.

Materials and methods. In the in vivo experimental study on male rabbits, the hemostatic effects of fibrin monomer (FM) (0.25 mg/kg) were evaluated in comparison with tranexamic acid (TA) (15 mg/kg) in post-traumatic parenchymal hemorrhage against the background of preliminary inhibition of platelet aggregation function with acetylsalicylic acid (2.0 mg/kg) and clopidogrel (8.0 mg/kg). Volume and rate of blood loss were estimated, as well as the parameters of the hemostatic system.

Results. It has been established that FM versus placebo when administered intravenously 1 hour before the injury can prevent severe bleeding associated with taking antiplatelet agents. The volume of blood loss after FM administration decreased in median by 6.0 times, the rate of blood loss – by 5.9 times, and when using TA – by 2.4 (РFM-TA < 0.02) and 4.8 times respectively. The hemostatic effects of TA were realized when the hemostatic balance was shifted towards the increased fibrin formation (an increase in the level of D-dimer in the blood plasma). The use of FM was not accompanied by any significant changes in the blood coagulation system.

Conclusion. The fibrin monomer at a dose of 0.25 mg/kg i.v. is capable of preventing severe  posttraumatic parenchymal bleeding caused by the combined use of drugs with different antiplatelet action. The phenomenon is not completely clear and needs to be analyzed in further research. The mechanism of hemostatic effects associated with FM is currently being studied.

1. Rossaint R., Bouillon B., Cerny V., Coats T.J., Duranteau J., Fernández-Mondéjar E., Filipescu D., Hunt B.J., Komadina R., Nardi G., Neugebauer E.A., Ozier Y., Riddez L., Schultz A., Vincent J.L., Spahn D.R. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit. Care. 2016; 20: 100. DOI: 10.1186/s13054-016-1265-x.

2. Gaussem P., Martin A.C., Belleville-Rolland T., Helley D., Bachelot-Loza C., Godier A. Antiplatelet agents and transfusion. Transfus. Clin. Biol. 2017; 24 (3): 160–165. DOI: 10.1016/j.tracli.2017.05.014.

3. Alamelu J., Liesner R. Modern management of severe platelet function disorders. Br. J. Haematol. 2010; 149 (6): 813–823. DOI: 10.1111/j.1365-2141.2010.08191.x.

4. Shi J., Ji H., Ren F., Wang G., Xu M., Xue Y., Chen M., Qi J., Li L. Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. JAMA Surg. 2013; 148 (6): 538–547. DOI: 10.1001/jamasurg.2013.1560.

5. Zahed R., Mousavi Jazayeri M.H., Naderi A., Naderpour Z., Saeedi M. Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Acad. Emerg. Med. 2018; 25 (3): 261–266. DOI: 10.1111/acem.13345.

6. Вдовин В.М., Момот А.П., Орехов Д.А., Толстокоров И.Г., Шевченко В.О., Красюкова В.О., Шахматов И.И., Лычёва Н.А., Белозерская Г.Г. Времязависимые системные гемостатические эффекты фибрин-мономера при дозированной травме печени. Казанский медицинский журнал. 2019; 100 (2): 257–263. DOI: 10.17816/KMJ2019-257.

7. Момот А.П., Вдовин В.М., Шахматов И.И., Толстокоров И.Г., Орехов Д.А., Шевченко В.О., Лычёва Н.А., Кудинов А.В., Белозерская Г.Г., Киселев В.И. Системные гемостатические и протромботические эффекты фибрин-мономера в эксперименте при дозированной травме печени. Сибирский научный медицинский журнал. 2019; 39 (1): 6–12. DOI: 10.15372/SSMJ20190101.

8. Вдовин В.М., Момот А.П., Красюкова В.О., Толстокоров И.Г., Орехов Д.А., Шевченко В.О., Шахматов И.И., Лычёва Н.А. Системные гемостатические и гемостазиологические эффекты фибрин-мономера при прямом ингибировании тромбина в эксперименте. Российский физиологический журнал. 2019; 105 (2): 207–2015. DOI: 10.1134/S0869813919020109.

9. Kyoung-Jin P., Eui-Hoon K., Hee-Jin K., Sun-Hee K. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J. Lab. Med. 2011; 31 (3): 143–147. DOI: 10.3343/kjlm.2011.31.3.143.

10. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2012; 1: 944.

11. Момот А.П., Шахматов И.И., Ломаев И.С., Терехов С.С. Способ промышленного получения фибрин-мономера из плазмы крови. Патент РФ № 2522237. 10.07.2014. Бюл. № 19.

12. Зиганшин А.У. Новые антиагреганты – блокаторы тромбоцитарных Р2-рецепторов. Казанский медицинский журнал. 2010; 91 (1): 73–79.